The largest relative pCR benefit was seen in patients with tumor cell PD-L1 expression < 1%; AEGEAN and CheckMate 816 reported pCR rates of 9% and 17% in the PD-L1 < 1% population6,9, compared with 31.3% in Arm 4 of the NeoCOAST-2 study. The gene discussed is CD274; the disease is neoplasm.